Journal
EXPERT REVIEW OF HEMATOLOGY
Volume 3, Issue 3, Pages 339-350Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/EHM.10.19
Keywords
bendamustine; bortezomib; cyclophosphamide; dexamethasone; enzastaurin; everolimus; lenalidomide; thalidomide; Waldenstrom macroglobulinemia
Categories
Funding
- Novartis
- Celgene
- GlaxoSmithKline
Ask authors/readers for more resources
Waldenstrom's macroglobulinemia (WM) is a B-cell lymphoproliferative disorder defined by bone marrow infiltration by lymphoplasmacytic cells as defined by the current classification systems. According to its transition situation between mutated chronic lymphocytic leukemia and multiple myeloma, several new therapeutic alternatives have been proposed for this entity based on the experience with these two well-known conditions together with the highly singular data provided by preclinical models. Thus, in WM two main therapeutic attitudes are possible: the use of conventional therapies based on the administration of single drugs or combinations with alkylating agents, purine analogues and anti-CD20 monoclonal antibodies; or the use of very new combinations that, without rejecting the previously mentioned drugs, include new agents, such as proteasome inhibitors, immunomodulatory agents or even histone deacetylase inhibitors and PI3K/AKT inhibitors, among others. Here we review the most recent results reported for the use of new combinations and new drugs in patients with WM at different stages of the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available